United States

AFFO (TTM)

AFFO/share (TTM)

AFFO/share Guidance

AFFO (Quarter)

AFFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/AFFO

Size (ft²)

Occupancy

The Company is a fully integrated REIT primarily focused on the ownership, acquisition, development and management of
retail properties net leased to industry leading tenants.

Agree Realty

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

As a long-term debt issuer, ADC is classified as investment grade

Period: 2023 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 13/15,
Adjusted FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2026 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 10/20,
Payout Ratio: 15/15,
Debt: 15/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's Adjusted FFO

Adjusted FFO Growth

Assessment of recent increases in Adjusted FFO per share, indicating profitability

Adjusted FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Company to host conference call today at 4:30 p.m. EDT LAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor â palbociclib

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6

Whitehawk Therapeutics Presents RealâWorld Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neur

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations Hangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113, a Core Technology of Whitehawk's ADC Platform Phase 1 Dose-Escalation Trials of HWK-007 and HWK-016 are Currently Enrolling; HWK-007 Trials-in-Progress Poster to be Presented at ASCO MORRISTOWN, N.J., May 21, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it entered into a new option agreement with Hangzhou DAC for access to CPT113 for use in up to five additional ADC programs.

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the expansion of internal capabilities to execute critical stages of its ACCUM®-enabled Antibody Drug Conjugates ("ADC") development pipeline. The Company has strengthened its purification, analytical characterization, conjugation development, and quality control ("QC") capabilities, while enhancing cellular testing and potency evaluation workflows within a more structured stage-gated framework to better support the advancement of its ADC partnership programs.

Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities

AstraZeneca and Daiichi Sankyo's ENHERTUÂ (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadj

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer

Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease PR Newswire

Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.267 per common share. The monthly dividend reflects an annualized dividend amount of $3.204 per common share, representing a 4.3% increase over the annualized dividend amount of $3.072 per common share from the second quarter of 2025. The dividend is payable June 12, 2026 to stockholders of.

Agree Realty Declares Monthly Common and Preferred Dividends

Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications

Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

BEIJING, May 06, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to initiate a clinical trial of its novel CDH17 targeted ADC, ICP-B208. CDH17 is a calcium-dependent cell adhesion protein that plays a key role in tumor cell proliferation, migration, and metastasis.

InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China

PARIS--(BUSINESS WIRE)--Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program. With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solution.

Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2026, and provided recent operational updates.

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

LAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 49,400 of the Company's common shares to two new employees on May 1, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients; first ADC combination trial with CR-001 on track to initiate in second half of 2026 Phase 1/2 trial of CR-003, an ITGB6-targeted ADC, ongoing in China CR-002, a PD-L1-targeted ADC, on track to enter the clinic in second half of 2026 Multiple key clinical data readouts anticipated beginning in Q1 2027 WALTHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the first quarter ended March 31, 2026 and recent business highlights.

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT to report financial results for the first quarter of 2026 and provide operational updates.

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

The 10-year Treasury yield sits at 4.26% and the Fed funds rate has been held at 3.75% for more than four months.

This Portfolio Pays Me Every Month (No Work Needed)

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter ended March 31, 2026. All per share amounts included herein are on a diluted per common share basis unless otherwise stated. First Quarter 2026 Financial and Operating Highlights: Invested approximately $424 million in 100 retail net lease properties 15 development or Developer Funding Platform ("DFP") projects completed or under construction with anticipated total cos.

Agree Realty Corporation Reports First Quarter 2026 Results

Results from early clinical studies across Junshi Biosciences' innovative pipeline were presented at the 2026 AACR, featuring: JS212 (EGFR/HER3 ADC), the J

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

SUZHOU, China, April 19, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that the Company presented the latest preclinical data for three proprietary pipeline assets at the American Association for Cancer Research (AACR) Annual Meeting (from April 17 to 22), including CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC). CStone's Proprietary ADC Technology Platform All three antibody-drug conjugates (ADCs) presented at AACR – CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC) – are developed utilizing CStone's proprietary ADC technology platform, which incorporates the following core features: High Stability & Precise Payload Release: The platform utilizes CStone's proprietary CSL20 linker, a hydrophilic construct designed for enhanced stability in circulation.

CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)

Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform Tumor regressions observed across various cancer models at low single ‑ digit mg/kg doses, with favorable tolerability (HNSTD 60 mg/kg) and low systemic levels of free payload (≤0.01% AUC) Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026 MORRISTOWN, N.J., April 19, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of new preclinical data across its ADC portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego, CA.

Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026

Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low breast cancer models, supporting its potential for patients with limited treatment options Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low breast cancer models, supporting its potential for patients with limited treatment options

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Passive income is revenue generated without the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.

Boomers and Gen X Love Passive Income From 5 of the Safest Monthly Dividend Stocks

Ingelheim, Germany  and  Shanghai , China /Cambridge, Mass.  –  15 April ,  202 6   – Boehringer Ingelheim and Zai Lab (NASDAQ: ZLAB; HKEX: 9688) today announced a clinical collaboration focused on pioneering a dual DLL3-targeting combination. The Phase Ib/II study will assess the safety, tolerability, and initial clinical activity of combining obrixtamig, Boehringer Ingelheim's DLL3/CD3 T-cell engager, with zocilurtatug pelitecan (zoci; formerly ZL‑1310), Zai Lab's DLL3-targeting ADC. The study will enroll patients with poorly differentiated NECs and extensive stage SCLC (ES-SCLC); diseases where patients urgently need more effective treatment options.

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

INCHEON, Korea--(BUSINESS WIRE)-- #ADC--Samsung Bioepis Co., Ltd. announced today the initiation of Phase 1 clinical trial for SBE303. SBE303 is Samsung Bioepis's first novel antibody-drug conjugate (ADC) candidate engineered to bind to Nectin-4, an adhesion protein that is specifically expressed in tumor cells, including urothelial cancer, lung cancer, and breast cancer.1 The Phase 1 clinical trial for SBE303 is an open‑label, multi-center, first‑in‑human trial to evaluate the safety, tolerability an.

Samsung Bioepis Initiates Phase 1 Clinical Trial for SBE303, Nectin-4 Targeting Antibody-Drug Conjugate (ADC) Candidate

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.267 per common share, representing a 1.9% month-over-month increase. The monthly dividend reflects an annualized dividend amount of $3.204 per common share, representing a 4.3% increase over the annualized dividend amount of $3.072 per common share from the second quarter of 2025. The divid.

Agree Realty Declares Increased Monthly Common Dividend

Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026 Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026

Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing

Shares of Agree Realty Corporation (NYSE: ADC - Get Free Report) have received an average rating of "Moderate Buy" from the fifteen analysts that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating

Agree Realty Corporation (NYSE:ADC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its first quarter 2026 operating results after the market closes on Tuesday, April 21, 2026. A conference call to discuss the Company's operating results is scheduled for Wednesday, April 22, 2026, at 9:00 AM ET. Interested parties and shareholders may access the call via teleconference or webcast: Teleconference: USA Toll Free (800) 715-9871   International (646) 307-196.

Agree Realty Announces First Quarter 2026 Earnings Release Date and Conference Call Information

LAUSANNE, Switzerland, April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on April 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment.

ADC Therapeutics Announces New Employee Inducement Grant

Exchange Traded Concepts LLC lessened its stake in shares of Agree Realty Corporation (NYSE: ADC) by 45.2% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 46,704 shares of the real estate investment trust's stock after selling 38,465 shares during the period. Exchange Traded Concepts

Exchange Traded Concepts LLC Has $3.36 Million Stock Position in Agree Realty Corporation $ADC

COMPANY TO HOST CONFERENCE CALL TODAY AT 4:30 P.M. EDT LAUSANNE, SWITZERLAND, JUNE 3, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT) TODAY ANNOUNCED TOPLINE DATA FROM ITS PHASE 3 LOTIS-5 CONFIRMATORY TRIAL EVALUATING ZYNLONTA (LONCASTUXIMAB TESIRINE-LPYL) IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL).

ADC THERAPEUTICS ANNOUNCES RESULTS FROM LOTIS-5 PHASE 3 CONFIRMATORY CLINICAL TRIAL OF ZYNLONTA IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

AGREEMENT WITH HANGZHOU DAC PROVIDES OPTION FOR UP TO FIVE NEW, INTERNALLY DEVELOPED ADC PROGRAMS, INCLUDING DUAL-PAYLOAD VARIATIONS HANGZHOU DAC'S DXC006 DATA AT ASCO REINFORCE CONVICTION FOR CPT113, A CORE TECHNOLOGY OF WHITEHAWK'S ADC PLATFORM PHASE 1 DOSE-ESCALATION TRIALS OF HWK-007 AND HWK-016 ARE CURRENTLY ENROLLING; HWK-007 TRIALS-IN-PROGRESS POSTER TO BE PRESENTED AT ASCO MORRISTOWN, N.J., MAY 21, 2026 /PRNEWSWIRE/ -- WHITEHAWK THERAPEUTICS, INC.(NASDAQ: WHWK), A CLINICAL-STAGE ONCOLOGY THERAPEUTICS COMPANY APPLYING ADVANCED TECHNOLOGIES TO ESTABLISHED TUMOR BIOLOGY TO EFFICIENTLY DELIVER IMPROVED ANTIBODY DRUG CONJUGATE (ADC)CANCER TREATMENTS, TODAY ANNOUNCED IT ENTERED INTO A NEW OPTION AGREEMENT WITH HANGZHOU DAC FOR ACCESS TO CPT113 FOR USE IN UP TO FIVE ADDITIONAL ADC PROGRAMS.

WHITEHAWK THERAPEUTICS EXPANDS ADC PIPELINE WITH NEW OPTION AGREEMENT FOR USE OF CPT113 LINKER-PAYLOAD

MONTREAL, QUEBEC--(NEWSFILE CORP. - MAY 19, 2026) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("DEFENCE" OR THE "COMPANY"), A PUBLICLY TRADED BIOTECHNOLOGY AND PRECISION INTRACELLULAR DRUG-DELIVERY COMPANY, IS PLEASED TO ANNOUNCE THE EXPANSION OF INTERNAL CAPABILITIES TO EXECUTE CRITICAL STAGES OF ITS ACCUM-ENABLED ANTIBODY DRUG CONJUGATES ("ADC") DEVELOPMENT PIPELINE. THE COMPANY HAS STRENGTHENED ITS PURIFICATION, ANALYTICAL CHARACTERIZATION, CONJUGATION DEVELOPMENT, AND QUALITY CONTROL ("QC") CAPABILITIES, WHILE ENHANCING CELLULAR TESTING AND POTENCY EVALUATION WORKFLOWS WITHIN A MORE STRUCTURED STAGE-GATED FRAMEWORK TO BETTER SUPPORT THE ADVANCEMENT OF ITS ADC PARTNERSHIP PROGRAMS.

DEFENCE THERAPEUTICS ENHANCES IN-HOUSE ADC DEVELOPMENT PLATFORM WITH EXPANDED ANALYTICAL AND CELLULAR TESTING CAPABILITIES

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.267 PER COMMON SHARE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.204 PER COMMON SHARE, REPRESENTING A 4.3% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.072 PER COMMON SHARE FROM THE SECOND QUARTER OF 2025. THE DIVIDEND IS PAYABLE JUNE 12, 2026 TO STOCKHOLDERS OF.

AGREE REALTY DECLARES MONTHLY COMMON AND PREFERRED DIVIDENDS

PATENT REINFORCES STRATEGIC FOUNDATION FOR LEAD ADC AKTX-101 AND EXPANDING ADC PIPELINE TO NEW MOLECULES TARGETING HIGH-VALUE ONCOLOGY INDICATIONS PATENT REINFORCES STRATEGIC FOUNDATION FOR LEAD ADC AKTX-101 AND EXPANDING ADC PIPELINE TO NEW MOLECULES TARGETING HIGH-VALUE ONCOLOGY INDICATIONS

AKARI THERAPEUTICS SECURES KEY EUROPEAN PATENT FOR ITS NOVEL RNA SPLICING MODULATOR ADC PAYLOAD, STRENGTHENING GLOBAL IP ESTATE FOR ALL MAJOR GLOBAL MARKETS

BEIJING, MAY 06, 2026 (GLOBE NEWSWIRE) -- INNOCARE PHARMA (HKEX: 9969; SSE: 688428), A LEADING BIOPHARMACEUTICAL COMPANY FOCUSING ON THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES, ANNOUNCED TODAY THAT THE CENTER FOR DRUG EVALUATION (CDE) OF THE CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) HAS APPROVED THE INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO INITIATE A CLINICAL TRIAL OF ITS NOVEL CDH17 TARGETED ADC, ICP-B208. CDH17 IS A CALCIUM-DEPENDENT CELL ADHESION PROTEIN THAT PLAYS A KEY ROLE IN TUMOR CELL PROLIFERATION, MIGRATION, AND METASTASIS.

INNOCARE ANNOUNCES APPROVAL OF CLINICAL TRIAL OF NOVEL CDH7 TARGETED ADC ICP-B208 IN CHINA

PARIS--(BUSINESS WIRE)--WAIV, FORMERLY OWKIN DX, A PARIS-BASED COMPANY CATALYZING AI PRECISION TESTING, TODAY ANNOUNCED IT HAS ENTERED A COLLABORATION WITH DAIICHI SANKYO (TSE: 4568) TO LEAD DIGITAL PATHOLOGY BIOMARKER DISCOVERY FOR AN ANTIBODY-DRUG CONJUGATE (ADC) PROGRAM. WITH DEEP EXPERTISE ACROSS DIVERSE PATHOLOGY AND MULTIMODAL DATA, AND A GLOBAL DATA NETWORK SPANNING ACADEMIC INSTITUTIONS, HOSPITALS, AND LABORATORIES, WAIV HAS A PROVEN TRACK RECORD DELIVERING AI-POWERED BIOMARKER SOLUTION.

WAIV ENTERS COLLABORATION WITH DAIICHI SANKYO TO DELIVER AI-DERIVED BIOMARKERS FOR ADC PROGRAM

LOTIS-5 PHASE 3 TOPLINE DATA EXPECTED IN SECOND QUARTER 2026, WITH FULL DATA FOR LOTIS-5 AND LOTIS-7 ANTICIPATED BY YEAR END FIRST QUARTER 2026 NET PRODUCT REVENUE OF $20.0 MILLION CASH AND CASH EQUIVALENTS OF $231.0 MILLION AS OF MARCH 31, 2026, WITH AN EXPECTED CASH RUNWAY AT LEAST INTO 2028 COMPANY TO HOST CONFERENCE CALL TODAY AT 8:30 A.M. EDT LAUSANNE, SWITZERLAND, MAY 4, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED RECENT OPERATIONAL UPDATES.

ADC THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATES

LAUSANNE, SWITZERLAND, MAY 1, 2026 /PRNEWSWIRE/ --ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE GRANTS OF OPTIONS TO PURCHASE AN AGGREGATE OF 49,400 OF THE COMPANY'S COMMON SHARES TO TWO NEW EMPLOYEES ON MAY 1, 2026 (EACH, A "GRANT"). THE GRANTS WERE OFFERED AS MATERIAL INDUCEMENT TO THE EMPLOYEES' EMPLOYMENT.

ADC THERAPEUTICS MAKES GRANTS TO NEW EMPLOYEES UNDER INDUCEMENT PLAN

ASCEND PHASE 1/2 GLOBAL CLINICAL TRIAL ONGOING, EVALUATING CR-001, A PD-1 X VEGF BISPECIFIC ANTIBODY, IN MULTIPLE SOLID TUMOR TYPES IN FIRST-LINE AND PREVIOUSLY TREATED PATIENTS; FIRST ADC COMBINATION TRIAL WITH CR-001 ON TRACK TO INITIATE IN SECOND HALF OF 2026 PHASE 1/2 TRIAL OF CR-003, AN ITGB6-TARGETED ADC, ONGOING IN CHINA CR-002, A PD-L1-TARGETED ADC, ON TRACK TO ENTER THE CLINIC IN SECOND HALF OF 2026 MULTIPLE KEY CLINICAL DATA READOUTS ANTICIPATED BEGINNING IN Q1 2027 WALTHAM, MASS., APRIL 29, 2026 (GLOBE NEWSWIRE) -- CRESCENT BIOPHARMA, INC. (CRESCENT OR THE COMPANY) (NASDAQ: CBIO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO RAPIDLY ADVANCING THE NEXT WAVE OF THERAPIES FOR CANCER PATIENTS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026 AND RECENT BUSINESS HIGHLIGHTS.

CRESCENT BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

LAUSANNE, SWITZERLAND, APRIL 27, 2026 /PRNEWSWIRE/ --ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT IT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST ON MONDAY, MAY 4, 2026, AT 8:30 A.M. EDT TO REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026 AND PROVIDE OPERATIONAL UPDATES.

ADC THERAPEUTICS TO HOST FIRST QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL ON MAY 4, 2026

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED RESULTS FOR THE QUARTER ENDED MARCH 31, 2026. ALL PER SHARE AMOUNTS INCLUDED HEREIN ARE ON A DILUTED PER COMMON SHARE BASIS UNLESS OTHERWISE STATED. FIRST QUARTER 2026 FINANCIAL AND OPERATING HIGHLIGHTS: INVESTED APPROXIMATELY $424 MILLION IN 100 RETAIL NET LEASE PROPERTIES 15 DEVELOPMENT OR DEVELOPER FUNDING PLATFORM ("DFP") PROJECTS COMPLETED OR UNDER CONSTRUCTION WITH ANTICIPATED TOTAL COS.

AGREE REALTY CORPORATION REPORTS FIRST QUARTER 2026 RESULTS

RESULTS FROM EARLY CLINICAL STUDIES ACROSS JUNSHI BIOSCIENCES' INNOVATIVE PIPELINE WERE PRESENTED AT THE 2026 AACR, FEATURING: JS212 (EGFR/HER3 ADC), THE J

JUNSHI BIOSCIENCES PRESENTS RESULTS FROM JS207 (PD-1/VEGF BSAB) PHASE 2 COMBO STUDIES AND JS212 (EGFR/HER3 ADC) FIH PHASE 1/2 STUDY AT AACR 2026

SUZHOU, CHINA, APRIL 19, 2026 /PRNEWSWIRE/ -- CSTONE PHARMACEUTICALS ("CSTONE," HKEX: 2616), AN INNOVATION-DRIVEN BIOPHARMACEUTICAL COMPANY FOCUSED ON THE RESEARCH AND DEVELOPMENT OF THERAPIES FOR ONCOLOGY, IMMUNOLOGY, INFLAMMATION, AND OTHER KEY DISEASE AREAS, TODAY ANNOUNCED THAT THE COMPANY PRESENTED THE LATEST PRECLINICAL DATA FOR THREE PROPRIETARY PIPELINE ASSETS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING (FROM APRIL 17 TO 22), INCLUDING CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), AND CS5008 (DLL3/SSTR2 ADC). CSTONE'S PROPRIETARY ADC TECHNOLOGY PLATFORM ALL THREE ANTIBODY-DRUG CONJUGATES (ADCS) PRESENTED AT AACR  CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), AND CS5008 (DLL3/SSTR2 ADC)  ARE DEVELOPED UTILIZING CSTONE'S PROPRIETARY ADC TECHNOLOGY PLATFORM, WHICH INCORPORATES THE FOLLOWING CORE FEATURES: HIGH STABILITY & PRECISE PAYLOAD RELEASE: THE PLATFORM UTILIZES CSTONE'S PROPRIETARY CSL20 LINKER, A HYDROPHILIC CONSTRUCT DESIGNED FOR ENHANCED STABILITY IN CIRCULATION.

CSTONE PRESENTED PRECLINICAL DATA FOR THREE NOVEL OR DIFFERENTIATED ADCS AT AACR 2026, INCLUDING CS5007 (EGFR/HER3)

DATA DEMONSTRATE PRECLINICAL PROOF-OF-CONCEPT FOR HWK-007, HWK-016 AND HWK-206, UNDERPINNED BY WHITEHAWK'S PROPRIETARY CARBON BRIDGE CYSTEINE RE-PAIRING PLATFORM TUMOR REGRESSIONS OBSERVED ACROSS VARIOUS CANCER MODELS AT LOW SINGLE  DIGIT MG/KG DOSES, WITH FAVORABLE TOLERABILITY (HNSTD 60 MG/KG) AND LOW SYSTEMIC LEVELS OF FREE PAYLOAD (0.01% AUC) PHASE 1 TRIALS FOR HWK-007 AND HWK-016 ARE ONGOING; AN IND SUBMISSION FOR HWK-206 IS ON TRACK FOR MID-2026 MORRISTOWN, N.J., APRIL 19, 2026 /PRNEWSWIRE/ -- WHITEHAWK THERAPEUTICS, INC.(NASDAQ: WHWK), A CLINICAL-STAGE ONCOLOGY THERAPEUTICS COMPANY APPLYING ADVANCED TECHNOLOGIES TO ESTABLISHED TUMOR BIOLOGY TO EFFICIENTLY DELIVER IMPROVED ANTIBODY DRUG CONJUGATE (ADC)CANCER TREATMENTS, TODAY ANNOUNCED THE PRESENTATION OF NEW PRECLINICAL DATA ACROSS ITS ADC PORTFOLIO AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2026, TAKING PLACE APRIL 17-22, 2026, IN SAN DIEGO, CA.

WHITEHAWK THERAPEUTICS PRESENTS COMPREHENSIVE PRECLINICAL DATA HIGHLIGHTING ITS NEXT-GENERATION ADC PORTFOLIO AT THE AACR 2026

ONVANSERTIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN DEMONSTRATED ENHANCED ANTITUMOR ACTIVITY, INCLUDING TUMOR REGRESSION AND APOPTOSIS IN HER2-LOW BREAST CANCER MODELS, SUPPORTING ITS POTENTIAL FOR PATIENTS WITH LIMITED TREATMENT OPTIONS ONVANSERTIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN DEMONSTRATED ENHANCED ANTITUMOR ACTIVITY, INCLUDING TUMOR REGRESSION AND APOPTOSIS IN HER2-LOW BREAST CANCER MODELS, SUPPORTING ITS POTENTIAL FOR PATIENTS WITH LIMITED TREATMENT OPTIONS

CARDIFF ONCOLOGY PRESENTS PRECLINICAL DATA ON ITS PLK1 INHIBITOR ONVANSERTIB IN COMBINATION WITH A HER2-TARGETED ADC AT THE 2026 AACR ANNUAL MEETING

INGELHEIM, GERMANY AND SHANGHAI , CHINA /CAMBRIDGE, MASS.  15 APRIL , 202 6  BOEHRINGER INGELHEIM AND ZAI LAB(NASDAQ: ZLAB; HKEX: 9688)TODAY ANNOUNCED A CLINICALCOLLABORATIONFOCUSED ONPIONEERINGADUALDLL3-TARGETINGCOMBINATION.THE PHASEIB/II STUDY WILL ASSESS THE SAFETY, TOLERABILITY, AND INITIAL CLINICAL ACTIVITY OF COMBININGOBRIXTAMIG, BOEHRINGER INGELHEIM'S DLL3/CD3T-CELLENGAGER, WITHZOCILURTATUGPELITECAN(ZOCI;FORMERLYZL1310), ZAILAB'SDLL3-TARGETINGADC.THE STUDYWILL ENROLLPATIENTS WITH POORLY DIFFERENTIATED NECS AND EXTENSIVE STAGE SCLC (ES-SCLC);DISEASESWHERE PATIENTS URGENTLY NEED MORE EFFECTIVE TREATMENTOPTIONS.

BOEHRINGER INGELHEIM AND ZAI LAB ANNOUNCE COLLABORATION ON DLL3TARGETING TCELL ENGAGER AND ADC COMBINATION IN SMALL CELL LUNG CANCER AND OTHER NEUROENDOCRINE CARCINOMAS

INCHEON, KOREA--(BUSINESS WIRE)-- #ADC--SAMSUNG BIOEPIS CO., LTD. ANNOUNCED TODAY THE INITIATION OF PHASE 1 CLINICAL TRIAL FOR SBE303. SBE303 IS SAMSUNG BIOEPIS'S FIRST NOVEL ANTIBODY-DRUG CONJUGATE (ADC) CANDIDATE ENGINEERED TO BIND TO NECTIN-4, AN ADHESION PROTEIN THAT IS SPECIFICALLY EXPRESSED IN TUMOR CELLS, INCLUDING UROTHELIAL CANCER, LUNG CANCER, AND BREAST CANCER.1 THE PHASE 1 CLINICAL TRIAL FOR SBE303 IS AN OPENLABEL, MULTI-CENTER, FIRSTINHUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY AN.

SAMSUNG BIOEPIS INITIATES PHASE 1 CLINICAL TRIAL FOR SBE303, NECTIN-4 TARGETING ANTIBODY-DRUG CONJUGATE (ADC) CANDIDATE

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.267 PER COMMON SHARE, REPRESENTING A 1.9% MONTH-OVER-MONTH INCREASE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.204 PER COMMON SHARE, REPRESENTING A 4.3% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.072 PER COMMON SHARE FROM THE SECOND QUARTER OF 2025. THE DIVID.

AGREE REALTY DECLARES INCREASED MONTHLY COMMON DIVIDEND

STRATEGIC PARTNERSHIP ENABLES AKARI TO ACCELERATE IND FILING BY LATE 2026 STRATEGIC PARTNERSHIP ENABLES AKARI TO ACCELERATE IND FILING BY LATE 2026

AKARI THERAPEUTICS ANNOUNCES STRATEGIC PARTNERSHIP WITH WUXI XDC TO ADVANCE DEVELOPMENT OF ITS NOVEL ADC PAYLOAD TARGETING RNA SPLICING

LAUSANNE, SWITZERLAND, APRIL 1, 2026 /PRNEWSWIRE/ --ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE A GRANT OF OPTIONS TO PURCHASE AN AGGREGATE OF 17,000 OF THE COMPANY'S COMMON SHARES TO A NEW EMPLOYEE ON APRIL 1, 2026 ("GRANT"). THE GRANT WAS OFFERED AS MATERIAL INDUCEMENT TO THE EMPLOYEE'S EMPLOYMENT.

ADC THERAPEUTICS ANNOUNCES NEW EMPLOYEE INDUCEMENT GRANT

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT IT WILL RELEASE ITS FIRST QUARTER 2026 OPERATING RESULTS AFTER THE MARKET CLOSES ON TUESDAY, APRIL 21, 2026. A CONFERENCE CALL TO DISCUSS THE COMPANY'S OPERATING RESULTS IS SCHEDULED FOR WEDNESDAY, APRIL 22, 2026, AT 9:00 AM ET. INTERESTED PARTIES AND SHAREHOLDERS MAY ACCESS THE CALL VIA TELECONFERENCE OR WEBCAST: TELECONFERENCE: USA TOLL FREE (800) 715-9871  INTERNATIONAL (646) 307-196.

Agree Realty

ADC

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC